Advertisement

Pharmaceutical Chemistry Journal

, Volume 48, Issue 4, pp 225–230 | Cite as

Synthesis and Antiarrhythmic Activity of N-[2-(1-Adamantylamino)-2-Oxoethyl]-N-(Aminoalkyl)Nitrobenzamides

  • A. M. Likhosherstov
  • S. A. Kryzhanovskii
  • G. V. Mokrov
  • V. N. Stolyaruk
  • M. B. Vititnova
  • I. B. Tsorin
  • T. A. Gudasheva
Search for New Drugs

A series of new substituted N-[2-(1-adamantylamino)-2-oxoethyl]-N-(ω-aminoalkyl)nitrobenzamides with an original spectrum of antiarrhythmic activity were synthesized. Their structure—activity relationship was studied. The most active compound, N-[2-(1-adamantylamino)-2-oxoethyl]-N-[3-(diethylamino)propyl]-4-nitrobenzamide hydrochloride, was selected as a potential lead drug for further detailed pharmacological and toxicological studies.

Keywords

N-[2-(1-adamantylamino)-2-oxoethyl]-N-(ω-aminoalkyl)nitrobenzamides antiarrhythmic activity N-[2-(1-adamantylamino)-2-oxoethyl]-N-[3-(diethylamino)propyl]-4-nitrobenzamide hydrochloride pharmacological characterization 

References

  1. 1.
    A. J. Camm and I. Savelieva, J. Interv. Card. Electrophysiol., 23(1), 7 – 14 (2008).PubMedCrossRefGoogle Scholar
  2. 2.
    S. Malhotra and M. K. Das, Future Cardiol., 7(2), 203 – 217 (2011).PubMedCrossRefGoogle Scholar
  3. 3.
    E. N. Prystowsky, B. J. Padanilam, S. Joshi, and R. I. Fogel, J. Am. Coll. Cardiol., 59(20), 1733 – 1744 (2012).PubMedCrossRefGoogle Scholar
  4. 4.
    C. E. Pollard, N. Abi Gerges, M. H. Brindgland-Taylor, et al., Br. J. Pharmacol., 159(1), 12 – 21 (2010).PubMedCentralPubMedGoogle Scholar
  5. 5.
    S. Kaab, D. C. Crawford, M. F. Sinner, et al., Circ. Cardiovasc. Genet., 5(1), 91 – 99 (2012).PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    D. M. Johnson, M. M. de Jong, H. J. Crijns, et al., Circ. Arrhythm. Electrophysiol., 5(1), 201 – 219 (2012).PubMedCrossRefGoogle Scholar
  7. 7.
    Y. Watanabe and J. Kimura, J. Pharmacol. Sci., 114(1), 111 – 114 (2010).PubMedGoogle Scholar
  8. 8.
    G. A. Baquero, J. E. Banchs, S. Depalma, et al., J. Cardiovasc. Electrophysiol., 23(3), 296 – 301 (2012).PubMedCrossRefGoogle Scholar
  9. 9.
    P. Manocha, V. Bavikati, J. Langberg, and M. S. Lloyd, Pacing Clin. Electrophysiol., 35(2), 170 – 173 (2012).PubMedCrossRefGoogle Scholar
  10. 10.
    P. Kirchhof and S. Nitschmann, Internist (Berl), 53(10), 1248 – 1250 (2012).CrossRefGoogle Scholar
  11. 11.
    L. Lin and R. Bai, Expert Opin. Drug Saf., 12(1), 5 – 8 (2013).PubMedCrossRefGoogle Scholar
  12. 12.
    R. G. Glushkov, S. D. Yuzhakov, A. I. L’vov, et al., Khim.-farm. Zh., 45(2), 3 – 12 (2011) [Pharm. Chem. J., 45(2), 65 – 74 (2011)].Google Scholar
  13. 13.
    Yu. A. Yuricheva, E. B. Maikov, S. F. Sokolov, et al., Kardiologiya, 51(1), 54 – 64 (2011).Google Scholar
  14. 14.
    S. Krishnamoorthy and G. Y. Lip, Expert Opin. Invest. Drugs, 18(8), 1191 – 1196 (2009).CrossRefGoogle Scholar
  15. 15.
    A. R. Khirti, E. M. Aliot, A. Capucci, et al., J. Cardiovasc. Electrophysiol., 23(5), 462 – 472 (2012).CrossRefGoogle Scholar
  16. 16.
    P. R. Kowey, H. J. Crijns, E. M. Aliot, et al., Circulation, 124(24), 2649 – 2660 (2011).PubMedCrossRefGoogle Scholar
  17. 17.
    P. F. Souney, W. D. Cooper, and D. J. Cushing, Expert Opin. Drug. Saf., 9(2), 319 – 333 (2010).PubMedCrossRefGoogle Scholar
  18. 18.
    D. J. Cushing, M. P. Adams, W. D. Cooper, et al., J. Clin. Pharmacol., 52(2), 214 – 221 (2011).CrossRefGoogle Scholar
  19. 19.
    H. Poppe, R. Schindler, W. Sauer, et al., Arch. Pharm. (Weinheim, Ger.), 332, 233 – 242 (1999).CrossRefGoogle Scholar
  20. 20.
    N. V. Kaverina, V. V. Lyskovtsev, S. F. Sokolov, et al., Vestn. Ross. Akad. Med. Nauk, No. 11, 42 – 46 (1998).Google Scholar
  21. 21.
    E. M. Vaughan Williams, Pharmacology of Antiarrhythmic Agents, L. Szekeres (ed.), Oxford (1981), pp. 120 – 150.Google Scholar
  22. 22.
    L. Szekeres and J. G. Papp, Handbook of Experimental Pharmacology, Springer Verlag, New York (1975), pp. 154 – 155.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • A. M. Likhosherstov
    • 1
  • S. A. Kryzhanovskii
    • 1
  • G. V. Mokrov
    • 1
  • V. N. Stolyaruk
    • 1
  • M. B. Vititnova
    • 1
  • I. B. Tsorin
    • 1
  • T. A. Gudasheva
    • 1
  1. 1.Zakusov State Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations